NCT07109427 Impact of an Electronic Health Record Maintenance Alert on PSA Screening Rates in a 10-Hospital Integrated Health System
| NCT ID | NCT07109427 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Washington University School of Medicine |
| Condition | Prostate Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 40,000 participants |
| Start Date | 2025-08-11 |
| Primary Completion | 2031-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40,000 participants in total. It began in 2025-08-11 with a primary completion date of 2031-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
\- The investigators propose a clinical trial to evaluate the impact of annual shared decision making for PSA screening, supported by system-level enhancements to promote evidence-based care: * Defined referral thresholds within the health maintenance reminder, aligned with clinical risk stratification per NCCN guidelines. * Enhanced clinical decision support (CDS) tools to reduce provider variation and ensure guideline-concordant screening and referral practices. * The goal is to reduce late-stage presentation without increasing overdiagnosis-ensuring that prostate cancer screening is both accessible and clinically effective.
Eligibility Criteria
Eligibility Criteria: * Receive care within the BJC Health System * Have had at least one primary care physician appointment in the calendar year of PSA screening (primary care) * Be male * Not have a history of prostate cancer * Meet one of the following risk criteria: * High Risk for Prostate Cancer * African American, between the ages of 40 and 75 (inclusive), or * Family history of prostate, breast, ovarian, and/or pancreatic cancer, or * Known familial germline mutation OR * Average Risk for Prostate Cancer * Between the ages of 50 and 75 (inclusive)
Contact & Investigator
Lannis Hall, M.D., MPH
PRINCIPAL INVESTIGATOR
Washington University School of Medicine
Frequently Asked Questions
Who can join the NCT07109427 clinical trial?
This trial is open to male participants only, aged 40 Years or older, up to 75 Years, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07109427 currently recruiting?
Yes, NCT07109427 is actively recruiting participants. Contact the research team at lannishall@wustl.edu for enrollment information.
Where is the NCT07109427 trial being conducted?
This trial is being conducted at St Louis, United States.
Who is sponsoring the NCT07109427 clinical trial?
NCT07109427 is sponsored by Washington University School of Medicine. The principal investigator is Lannis Hall, M.D., MPH at Washington University School of Medicine. The trial plans to enroll 40,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.